News Section
Origin Biomedicals Has Been Listed on the Emerging Stock Market, Positioning Itself as the First Military-Industrial Biomedical Stock
2024-03-29
Today (29th), Origin Biomedical (6483) debuted on the Emerging Stock Market at a reference price of NT$20 per share, focusing on the development of multiple 505(b)(2) new drugs. These include OBM-B01 for the prevention and treatment of cyanide poisoning from fire inhalation, as well as OBM-A01 for the prevention and treatment of radiation injuries.
